Proactive Investors - Run By Investors For Investors

Award-winning pain consultant appointed to Sativa Investments’ advisory board

“The new Home Office guidelines determining the prescription of Medicinal Cannabis encompass the treatment of pain and nausea in cancer patients. Matthew's qualifications and research in this area add even further to the input of Sativa's top-level Medicinal Cannabis Advisory Board.”
cannabis
Sativa is the UK’s first medical cannabis investment vehicle

Sativa Investments PLC (NEX:SATI) has appointed an award-winning pain medicine and anaesthetic consultant to its medical cannabis advisory board.

Matthew Brown is a consultant at the Royal Marsden hospital in West London and recently published research into using cannabinoids for cancer pain treatment.

READ: Sativa announces £3.75mln equity raise

Last month, the UK government gave doctors the green light to prescribe cannabis products to patients for the first time ever.

“The new Home Office guidelines determining the prescription of Medicinal Cannabis encompass the treatment of pain and nausea in cancer patients,” said founder and chief executive Geremy Thomas.

“Matthew's qualifications and research in this area add even further to the input of Sativa's top-level Medicinal Cannabis Advisory Board. Patient outcome is the clear driver in the highly sensitive and prevalent area of cancer treatment.”

View full SATI profile View Profile

Sativa Investments Timeline

Related Articles

pills
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use